On August 3, 2026, Amneal Pharmaceuticals LLC entered into Amendment No. 3 to its Term Loan Credit Agreement with JPMorgan Chase Bank and other lenders. The amendment converted existing term loans into new loans totaling $2.039 billion and incurred an additional $45.2 million in new debt. Proceeds from the new loan were used to prepay non-converted existing loans at par. The repricing reduces interest rate margins by 50 basis points, resulting in estimated annualized cash interest savings of approximately $12 million. The maturity date remains August 1, 2032. Amneal Pharmaceuticals operates in the pharmaceutical industry, specializing in generic and specialty medications.
